Open AccessRadionuclide therapy with alpha-emitters
Author(s) -
D. Dzhuzha Prof.,
S. Myasoyedov Prof.
Publication year - 2019
Publication title -
radiation diagnostics, radiation therapy
Language(s) - English
Resource type - Journals
eISSN - 2707-0700
pISSN - 2707-0697
DOI - 10.37336/2707-0700-2019-4-4
Subject(s) - bismuth , radium , radionuclide , alpha (finance) , radiochemistry , radioresistance , alpha particle , nuclear medicine , polonium , astatine , medicine , radiation therapy , chemistry , physics , nuclear physics , construct validity , nursing , patient satisfaction , organic chemistry , quantum mechanics , voltage
In this review the main streams of using alpha-emitters radium-223, actinium-225, bismuth-213, astatine-211 in complex treatment of malignant tumors are reviewed. The features of radiobiological actions of alpha-emission make its more effective in hundred times than beta-emission. The efficacy of this kind of radionuclide therapy does not dependent from chemoresistance and radioresistance to beta-emitters. The results of experimental and initial clinical investigation, which indicate on promising further investigations in this direction, were revealed.Key words: radionuclide therapy of malignant tumors, alpha-emitters, radium-223, actinium-225, bismuth-213, astatine-211.